U.S. Markets closed

PYC Therapeutics Invited to Participate in the SVB Leerink Biopharma Private Company Connect

  • Oops!
    Something went wrong.
    Please try again later.
·2 min read
  • Oops!
    Something went wrong.
    Please try again later.

NEW YORK and PERTH, Australia, March 22, 2021 /PRNewswire/ -- PYC Therapeutics (ASX: PYC), a biotechnology company developing a new generation of precision RNA therapeutics to change the lives of patients with inherited diseases, today announced it was invited to participate as one of a select group of companies at the SVB Leerink Biopharma Private Company Connect, taking place virtually on March 25-26, 2021.

(PRNewsfoto/PYC Therapeutics)
(PRNewsfoto/PYC Therapeutics)

Members of PYC's management team will participate in one-on-one meetings with U.S biotech and life science investors during both days of the virtual event.

About PYC Therapeutics

PYC Therapeutics (ASX: PYC) is a development-stage biotechnology company pioneering a new generation of RNA therapeutics that utilize Cell Penetrating Peptides (CPPs), a revolutionary delivery technology designed to overcome the major challenges of current gene-based therapies. PYC believes its CPP technology provides safer, more effective access for a wide range of potent and precise drug cargoes to the highest value drug targets that exist inside cells. The Company is leveraging its leading-edge science to develop a pipeline of novel therapies with an initial focus on inherited eye diseases for which it has unveiled three preclinical stage assets. PYC's discovery and laboratory operations are located in Australia and the Company recently launched an expansion into the U.S. for its preclinical, clinical, regulatory and business development operations. For more information, visit pyctx.com, or follow us on LinkedIn and Twitter.

Forward looking statements

Any forward-looking statements in this ASX announcement have been prepared on the basis of a number of assumptions which may prove incorrect and the current intentions, plans, expectations and beliefs about future events are subject to risks, uncertainties and other factors, many of which are outside the Company's control. Important factors that could cause actual results to differ materially from assumptions or expectations expressed or implied in this ASX announcement include known and unknown risks. Because actual results could differ materially to assumptions made and the Company's current intentions, plans, expectations and beliefs about the future, you are urged to view all forward-looking statements contained in this ASX announcement with caution. The Company undertakes no obligation to publicly update any forward-looking statement whether as a result of new information, future events or otherwise.

CONTACTS:




INVESTORS

MEDIA

Deborah Elson/Matthew DeYoung

Leo Vartorella

Argot Partners

Argot Partners

deborah@argotpartners.com

leo@argotpartners.com

matthew@argotpartners.com


Cision
Cision

View original content to download multimedia:http://www.prnewswire.com/news-releases/pyc-therapeutics-invited-to-participate-in-the-svb-leerink-biopharma-private-company-connect-301252405.html

SOURCE PYC Therapeutics